Package Leaflet: Information for the User
PREZISTA 150 mg film-coated tablets
darunavir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
Contents of the pack and other information
What is PREZISTA?
PREZISTA contains the active substance darunavir. PREZISTA is an antiretroviral medicine used to treat infection by the Human Immunodeficiency Virus (HIV). It belongs to a group of medicines called protease inhibitors. PREZISTA reduces the amount of HIV in your body. This improves your immune system and reduces the risk of diseases associated with HIV infection.
What is it used for?
PREZISTA is used to treat adults and children from 3 years of age and at least 15 kg in weight who are infected with HIV and have already used other antiretroviral medicines.
PREZISTA must be taken with a low dose of ritonavir and other HIV medicines. Your doctor will discuss the most suitable combination of medicines with you.
Do not take PREZISTA
Do not combine PREZISTA with any of the following medicines
If you are taking any of these medicines, consult your doctor to change to another medicine.
Do not combine PREZISTA with products that contain St. John's Wort (Hypericum perforatum).
Warnings and precautions
Consult your doctor, pharmacist, or nurse before you start taking PREZISTA.
PREZISTA does not cure HIV infection. While you are taking this medicine, you may still transmit HIV to others, although effective antiviral treatment reduces the risk. Consult your doctor about the precautions needed to avoid infecting others.
People taking PREZISTA may develop other infections or diseases associated with HIV infection. You must keep in regular contact with your doctor.
People taking PREZISTA may develop a skin rash. It is not common for the rash to be severe or life-threatening. Please consult your doctor if you develop a rash.
Patients taking PREZISTA and raltegravir (for HIV infection) may develop rashes (usually mild or moderate) more frequently than patients taking either of the two medicines separately.
Tell your doctor about your situation BEFORE and DURING treatment
Make sure you check the following points and tell your doctor if any apply to you.
These symptoms are thought to be due to an improvement in the body's immune response, enabling it to fight off infections that were already present but not yet showing any symptoms.
Elderly population
PREZISTA has only been used in a limited number of patients aged 65 years or older. If you belong to this age group, please talk to your doctor to see if you can use PREZISTA.
Children
PREZISTA is not used in children under 3 years of age or weighing less than 15 kg.
Taking PREZISTA with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Some medicines must not be takenwith PREZISTA. The list can be found in the section “Do not combine PREZISTA with any of the following medicines:”
In most cases, PREZISTA can be combined with HIV medicines from other classes [e.g., NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists, and FIs (fusion inhibitors)]. PREZISTA has not been tested with ritonavir with all HIV protease inhibitors and must not be used with other HIV protease inhibitors. In some cases, it may be necessary to change the dose of the other medicines. Therefore, if you are taking other anti-HIV medicines, always tell your doctor and follow their instructions carefully on which medicines can be combined.
The following products may reduce the effectiveness of PREZISTA. Tell your doctor if you are taking:
PREZISTA may also affect the action of other medicines. Tell your doctor if you are taking:
In certain cases, it may be necessary to modify the dose of some medicines because when combined, the therapeutic or adverse effects of these or PREZISTA may be affected.
Tell your doctor if you are taking:
This is nota complete list of medicines. Tell your doctor about allthe medicines you are taking.
Taking PREZISTA with food and drink
See section 3 “How to take PREZISTA.”
Pregnancy and breastfeeding
Tell your doctor immediately if you are pregnant, plan to become pregnant, or are breastfeeding. Pregnant or breastfeeding women must not take PREZISTA with ritonavir unless their doctor specifically instructs them to do so. Pregnant or breastfeeding women must not take PREZISTA with cobicistat.
It is recommended that women infected with HIV do not breastfeed their babies because there is a possibility that the babies could be infected with HIV through breast milk, as well as the unknown effects of the medicine on the baby.
Driving and using machines
Do not drive or use machines if you experience dizziness after taking PREZISTA.
Follow the administration instructions for the medicine contained in this leaflet or as indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse.
Do not stop taking PREZISTA or ritonavir without consulting your doctor first, even if you feel better.
Once treatment has started, the dose or form of the dose should not be changed or treatment interrupted without consulting a doctor.
Dose for children from 3 years of age, with at least 15 kilograms of weight who have not taken antiretroviral medications before (the doctor will determine this)
The doctor will calculate the correct daily dose based on the child's weight (see the table below). This dose should not exceed the recommended adult dose, which is 800 milligrams of PREZISTA along with 100 milligrams of ritonavir once a day.
The doctor will inform you about how many PREZISTA tablets and how much ritonavir (capsules, tablets, or solution) the child should take.
Dose for children from 3 years of age, with at least 15 kilograms of weight who have taken antiretroviral medications before (the doctor will determine this)
The doctor will establish the correct dose based on the child's weight (see the table below). The doctor will determine if a once-daily or twice-daily dose is appropriate for the child. This dose should not exceed the recommended adult dose, which is 600 milligrams of PREZISTA along with 100 milligrams of ritonavir twice a day or 800 milligrams of PREZISTA along with 100 milligrams of ritonavir once a day. The doctor will inform you about how many PREZISTA tablets and how much ritonavir (capsules, tablets, or solution) the child should take. Other concentrations of the tablets are available, and your doctor may prescribe a specific combination of tablets to achieve the appropriate dosage.
The oral suspension of PREZISTA is also available. Your doctor will tell you if PREZISTA tablets or the oral suspension are suitable for the child.
Dose twice a day
Instructions for children
Dose for adults who have not taken antiretroviral medications before (to be determined by your doctor)
You will require a different dose of PREZISTA that cannot be administered with these 75-milligram tablets. Other concentrations of PREZISTA are available.
Dose for adults who have taken antiretroviral medications before (to be determined by your doctor)
The dose is:
Or
Please talk to your doctor about which dose is correct for you.
Instructions for adults
Child-resistant cap removal
The plastic bottle has a child-resistant safety cap and is opened as follows:
|
If you take more PREZISTA than you should
Inform your doctor, pharmacist, or nurse immediately.
If you forget to take PREZISTA
If you realize within 6 hours, take the tablets immediately. Always with ritonavir and with food. If you realize after 6 hours, skip that dose and do the next one as usual. Do not take a double dose to make up for forgotten doses.
Do not stop taking PREZISTA without talking to your doctor first
HIV medications can make you feel better. Even if you feel better, do not stop taking PREZISTA. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Tell your doctor if you develop any of the following side effects.
There have been reports of liver problems that can occasionally be severe. Your doctor will perform a blood test before you start treatment with PREZISTA. If you have a chronic infection caused by hepatitis B or C, your doctor will frequently check your blood tests, as there is a greater likelihood of developing liver problems. Talk to your doctor about the signs and symptoms of liver problems. These may include yellowing of the skin and the whites of the eyes, darkening (tea color) of the urine, pale stools (bowel movements), nausea, vomiting, loss of appetite, or pain, discomfort, or tenderness in the right side below your ribs.
Skin rash (more frequent when used in combination with raltegravir), itching. The skin rash is usually mild to moderate. A skin rash can also be a symptom of a rare and serious situation. Therefore, it is essential to talk to your doctor if you present a rash. Your doctor will advise you on how to control the symptoms or if you should interrupt PREZISTA.
Other serious side effects were diabetes (frequent) and pancreatitis (uncommon).
Very common side effects (may affect more than 1 in 10 patients)
Common side effects (may affect up to 1 in 10 patients)
Uncommon side effects (may affect up to 1 in 100 patients)
Rare side effects (may affect up to 1 in 1,000 patients)
Some side effects are typical of HIV medications that belong to the same family as PREZISTA. These are:
Reporting side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the bottle, after EXP. The expiration date is the last day of the month indicated.
PREZISTA does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any medication you no longer need. This will help protect the environment.
Composition of PREZISTA
Appearance of the product and package contents
Coated tablet, white, oblong, marked with TMC on one side and 150 on the other side.
240 tablets in a plastic bottle.
PREZISTA is also available in 75-milligram, 300-milligram, 400-milligram, 600-milligram, and 800-milligram coated tablets and a 100 milligrams per milliliter oral suspension.
Marketing authorization holder
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Manufacturer
Janssen-Cilag SpA, Via C. Janssen, Borgo San Michele, 04100 Latina, Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com | Lithuania UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com |
Bulgaria "JOHNSON & JOHNSON" Bulgaria EOOD Tel: +359 2 489 94 00 jjsafety@its.jnj.com | Luxembourg Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com |
Czech Republic Janssen-Cilag s.r.o. Tel: +420 227 012 227 | Hungary Janssen-Cilag Kft. Tel: +36 1 884 2858 |
Denmark Janssen-Cilag A/S Tel: +45 4594 8282 jacdk@its.jnj.com | Malta AM MANGION LTD Tel: +356 2397 6000 |
Germany Janssen-Cilag GmbH Tel: +49 2137 955 955 jancil@its.jnj.com | Netherlands Janssen-Cilag B.V. Tel: +31 76 711 1111 janssen@jacnl.jnj.com |
Estonia UAB "JOHNSON & JOHNSON" Estonian branch Tel: +372 617 7410 ee@its.jnj.com | Norway Janssen-Cilag AS Tel: +47 24 12 65 00 jacno@its.jnj.com |
Greece Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε. Tel: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
Spain Janssen-Cilag, S.A. Tel: +34 91 722 81 00 infojaces@its.jnj.com | Poland Janssen-Cilag Polska Sp. z o.o. Tel: +48 22 237 60 00 |
France Janssen-Cilag Tel: 0 800 25 50 75 / +33 1 55 00 40 03 medisource@its.jnj.com | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Croatia Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com | Romania Johnson & Johnson Romania SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenia Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 Janssen_safety_slo@its.jnj.com |
Italy Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com | Finland Janssen-Cilag Oy Tel: +358 207 531 300 jacfi@its.jnj.com |
Cyprus Βαρνάβας Χατζηπαναγής Λtd Tel: +357 22 207 700 | Sweden Janssen-Cilag AB Tel: +46 8 626 50 00 jacse@its.jnj.com |
Latvia UAB "JOHNSON & JOHNSON" Latvian branch Tel: +371 678 93561 lv@its.jnj.com | United Kingdom Janssen-Cilag Ltd. Tel: +44 1 494 567 444 |
Date of the last revision of this leaflet:{MM/YYYY}.
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.